Neurologic manifestations will not be prevented with folic acid, and if not treated with vitamin B 12, irreversible damage will result
The figures and targets here are research hypotheses, not established outcomes
The three phases are activation in weeks 14, remodeling in weeks 58, and maintenance in weeks 912
Animal studies on BPC-157 have demonstrated a favorable safety profile, with no established LD50 (lethal dose) and no documented organ toxicity, carcinogenicity, or mutagenicity at tested doses
Austin Research Products LLC (d/b/a PeptidePlugs) is a research material supplier - we are not a compounding pharmacy or compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act, nor an outsourcing facility as defined under Section 503B